We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Gene Expression Levels Measured in a Variety of Sample Types

By LabMedica International staff writers
Posted on 12 Nov 2009
Print article
A quantitative nuclease protection assay (qNPA) process will be applied microarrays to enable rapid and efficient measuring of gene expression levels in a variety of sample types.

Roche NimbleGen (Madison, WI, USA) and High Throughput Genomics (HTG; Tucson, AZ, USA), provider of the quantitative nuclease protection assay (qNPA), have entered into a supply agreement. Roche NimbleGen will provide HTG with high-density, multiplex DNA microarray slides for advanced gene-expression analysis. HTG will apply the company's quantitative nuclease-protection assay (qNPA) process to the microarrays to enable rapid and accurate measurements of the gene-expression levels in a variety of sample types.

The agreement enhances HTG's existing service capability offering with the ability to take a broader look at gene expression through the multiplex capability of the Roche NimbleGen microarrays. Sample preparation using qNPA technology allows for a much simpler, more cost-effective workflow versus traditional labeling methods, while the Roche NimbleGen multiplex technology offers a cost-effective high-density microarray providing in depth gene-expression information.

Gerd Maass, CEO of Roche NimbleGen said, "The partnership with HTG showcases the strengths of the two companies and the flexibility of the NimbleGen Arrays by pairing two innovative technologies to provide flexibility, time savings, and cost savings while offering the significant in depth genetic information that our high-density arrays provide."

Roche NimbleGen, Inc. is a manufacturer and supplier of a suite of DNA microarrays, consumables, instruments, and services. NimbleGen's Maskless Array Synthesis (MAS) technology uses digital light to produce high-density arrays of long oligo probes that provide information content and higher data quality necessary for studying the full diversity of genomic and epigenomic variation. Scientists can thus obtain a clearer understanding of genomic and epigenomic structure and function and how they impact medicine and biology.

Related Links:

Roche NimbleGen
High Throughput Genomics


New
Gold Member
Syphilis Screening Test
VDRL Antigen MR
Antipsychotic TDM AssaysSaladax Antipsychotic Assays
New
Urine Strips
11 Parameter Urine Strips
New
Nuclear Matrix Protein 22 Test
NMP22 Test

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.